NCT00254423View on ClinicalTrials.gov

Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

November 8, 2005

Primary Completion Date

March 14, 2025

Study Completion Date

March 14, 2025

Conditions
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositivePhiladelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
Interventions
DRUG

Dasatinib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00254423 - Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia | Biotech Hunter | Biotech Hunter